Hormone therapy and breast cancer: conflicting evidence

Cindy Farquhar Cochrane Menstrual Disorders and Subfertility Group




The world of hormone therapy in the 1990's

Throughout the 1970s, 1980s and 1990s long term use of HRT was widely recommended for women after the menopause

- Suggested Benefits: prevention of hot flushes, osteoporosis, heart disease, ageing, improved cognition
- Possible harms: breast cancer, venous thromboembolism

Balancing the benefits and harms





HRT and Breast Cancer is not a new story.....

- Berquivist (1992) RR of breast cancer in HRT users 1.6
- Nurses Health study (1995) RR 1.45 after >5 years use of HRT
- Lancet Collaborative meta analysis (1997) RR 1.35 after >5 years of HRT

Lancet Collaborative Group

- Meta analysis of 51 observational studies on breast cancer risk and HRT use
- 52,000 women with breast cancer
- Majority on ERT
- Adjusted for age of menopause
- Main findings:
 - RR of breast cancer diagnosis 1.35 after 5 + years of HRT
 - No increased risk in past users (>5 years)
 - Risk greater in slim women than overweight (BMI >25) women
 - Family history of breast cancer did not increase risk
 - No increased risk of mortality
 - No difference between ERT and HRT



Design of WHI study

POPULATION:

- 16,608 women aged 50 to 79 years
- Population based sample (recruited from mailing and media awareness)
- Heterogeneous group minimal exclusions
- Washout period before trial
- Two study groups: HRT and ERT



What sort of women were in the trial?

Age: 50-79 years with mean of 63 years
70% overweight, 45% BMI ≥ 30
Ethnically diverse
20% prior HRT use, 6% current users


WHI results for HRT: July 2002

Cases per 10,000 women per year

	HRT	placebo	Additional events/1,000	NNT for 1 additional event
Breast cancer	38	30	+8	1250
Heart disease	37	30	+7	1430
Stroke	26	13	+7	1250
DVT	29	21	+8	550
Fracture	10	15	-5	2000
Colorectal cancer	10	16	-б	1667

No overall increase in death rates at 5.2 years of follow up





Progestin 8506 8396 8303 8194 7943 5751 3013 1302 Placebo 8102 8002 7895 7793 7581 5430 2696 977

Prior use of HRT increased risk cf with no prior use of HRT MR 2.13 (1.15-3.94) for prior use MR 1.06 (0.81-1.38) for no prior use Adherent to therapy increased risk MR 1.49

ERT only study: 2004

 No effect on BC diagnoses reported after 6.8 years follow up
 HR 0.77 (nominal 95%CI 0.59-1.01 and adjusted 95% CI 0.57-1.06)
 Mortality from BC: no difference but no HR provided

Million Women Study – Aug 03

 1996-2001: National Health Service Breast Screening Programme invited women to take part prior to entry
 1084110 women, 50-64 years
 50% of women had used HRT

18 % had BMI ≥ 30

Articles

Breast cancer and hormone-replacement therapy in the Million Women Study

THE LANCET • Vol 362 • August 9, 2003 • www.thelancet.com

Million Women Study


Relative Risk

- E only 1.3 (1.21-1.40)
- ▶ E+P 2.0 (1.88-2.12)

Current users of HRT cf never users

- Diagnosis of BC: adj RR 1.66 (1.58-1.75)
- Mortality from BC: 1.22 (1.00-1.48)
- Past users of HRT: no increased risk

No differences: formulations and delivery systems



igure 2: Relative risk of incident invasive breast cancer in relation to recency and type of HRT used

Mortality from BC in MWS

HRT use at baseline	Deaths/population		Relative risk (95% FCI)*
Never users	238/392 757	1.00 (0.88-1.14)	
Current users	191/285 987	1.22 (1.05–1.41)	
Past users	88/150 179	1.05 (0.85–1.29)	

Figure 6: Relative risk of fatal breast cancer in relation to use of HRT at baseline

FCI=floated CI. *Relative to never users, stratified by age, time since menopause, parity and age at first birth, family history of breast cancer, body-mass index, region, and deprivation index.

0.5

1.0

1.5



Authors conclusions

10 years of HRT is estimated to result in
 5 additional cancers per 1000 users of E only
 19 additional cancers per 1000 users of E+P
 Use of HRT by women 50-64 yrs in UK in past decade has resulted in an estimated 20,000 extra breast cancers (15,000 from E + P)

Summary of WHI and MWS: RR

	WHI –	WHI – E	MWS –	MWS – E
	E+P	only	E+P	only
Br Ca ∆	1.26 (1.02-	0.79 (0.61-	2.0 (1.88-	1.3 (1.21-
	1.56)	1.02)	2.12)	1.40)
BC	0.95 (0.24-	Not	1.22 (1.05-	Not
mortality	38.1)	reported	1.41)	reported
Time frame	5.6 years	6.8 years	4.1 years	4.1 years

Cochrane Review

 Review:
 Long term hormone therapy for perimenopausal and postmenopausal women

 Comparison:
 05 All women (Selected outcomes: cancer, cholecystic disease, fractures)

 Outcome:
 02 Breast cancer: Oestrogen-only HT (moderate dose)

Study	Treatment n/N	Control n/N	Relative Risk (Fixed) 95% Cl	Weight (%)	Relative Risk (Fixed) 95% CI
01 Oestradiol 1mg for 2 yrs			1.11		
EPAT 2001	0/111	17111 -		100.0	0.33 [0.01, 8.10]
Subtotal (95% CI)	0/111	1/111 -		100.0	0.33 [0.01, 8.10]
Test for heterogeneity chi-square			_		
Test for overall effect=-0.68 p=0.	5				
02 CEE 0.625 for 2.8 - 3.2 yrs					
ERA 2000	17100	0 / 105	2 <u></u>	24.6	3.15 [0.13, 76.40]
PEPI 1995	1/175	1/174		50.6	0.99 [0.06, 15.77]
WAVE 2002	1 /60	0/62		24.8	3.10 [0.13, 74.60]
Subtotal (95% CI) Test for heterogeneity chi-square Test for overall effect=0.83 p=0.4		1/341 198		100.0	2.05 [0.38, 11.04]
03 CEE 0.625 mg for 6.8 yrs					
WHI 1998	9475310	124/5429	-	100.0	0.78 [0.59, 1.01]
Subtotal (95% CI) Test for heterogeneity chi-square Test for overall effect=-1.88 p=0.		124/5429	+	100.0	0.78 [0.59, 1.01]
		.01	.i i 10	100	
			Favours treatment Favours contro	L	



WHI and MWS: consistency?

	WHI	MWS
BCA E+P	Increased	Increased
BC mortality E+P	No difference	Increased
BC A E only	No difference	Increased
BC mortality E only	Not reported	Not reported

Possible explanation for the differences

Study design RCT versus observational Power 16,000 women versus 1,000,000 **W** US vs UK pop Differences in screening etc Prior use of hormones № 72% E+P (WHI), 52% E (WHI) versus 50% in MWS Younger age in MWS Mean 63yrs E+P (WHI), 63 E (WHI) versus 56 years (MWS) D BMI Women in WHI study heavier than women in MWS



Explanation for the differences: BMI amongst Estrogen only in MWS

BMI Kg/m ²	RR of BC Δ MWS	MWS	WHI 2004
< 25	1.36 (1.14- 1.63)	45%	21%
25-29	1.14 (0.94- 1.40)	37%	34%
≥ 30	0.99 (0.73- 1.34)	18%	45%



Weight and breast cancer

Overweight women have increased risk of breast
 In MWS trial women with BMI < 25 had increased risk





Conclusions

Authors of trial concluded that:

- IRT should not be used for long-term disease prevention because the benefits were not sufficient to justify the risks.
- On balance the harm of HRT was greater than the benefit (global index)
- The trial was not designed to assess the effects of HRT for short term use to control menopausal symptoms



Intervention/comparison

Combined HRT study

- Conjugated equine oestrogens 0.625mg/day + medroxyprogesterone acetate 2.5mg/day in 1 tablet
- Placebo tablet, 1 tablet
- Participants and study staff blinded but unblinding occurred because of need to treat bleeding

Estrogen only study

- Women who had undergone hysterectomy
- Conjugated equine oestrogens 0.625mg/day
- Placebo tablet



Time period of trial

- Recruitment from 1993 1998
- Average follow up 5.2 years
- Planned duration 8.5 years (until 2005)
- Trial stopped early because:
 - Test statistic for invasive breast cancer exceeded the stopping boundary
 - Global index statistic supported risks exceeding benefits



Outcomes

Primary CHD rates – HRT expected to be a benefit Invasive breast cancer rates – HRT expected to be a harm Other outcomes Mip fracture and other fracture rates Stroke rates VTE rates Endometrial cancer rates Colorectal cancer rates Total death rates Global index

Lancet Editorial Dec 2004

"But the HRT story is an all too familiar one in modern medicine. A new drug is found to be potentially useful in a large proportion of the population. Hypotheses for extended use, in the case of HRT to prevent cardiovascular disease and bone fractures, are generated from observational studies. Its use is then heavily promoted beyond the initial indication. Rigorously conducted randomised studies with long enough followup are scarce or lacking. Harm and risk are uncovered many years after widespread use. "